FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Fulcrum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.70+0.05 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -77.7% | -25.3% | |
| Return on assets | – | -59.0% | -23.9% | |
| Current ratio | – | 4.47 | 27.40 | |
| Capex to revenue | – | 15.2% | – | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Fulcrum Therapeutics generated $328.78M from operations and spent $4.78M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$328.78M
Used
$4.78M
Capital expenditure$4.78M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-12.2%
×Asset turnover0.31×
×Equity multiplier1.08×
=Return on equity, FY2024-4.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -12.2% | 0.31× | 1.08× | -4.1% |
| FY2023 | -3470.1% | 0.01× | 1.12× | -44.8% |
| FY2022 | -1732.4% | 0.03× | 1.12× | -53.5% |
| FY2021 | -421.9% | 0.11× | 1.19× | -52.7% |
| FY2020 | -802.7% | 0.07× | 1.32× | -77.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$74.88M
- Cash generatingOperating cash flow above zero-$60.07M
- Return on assets improvedROA up on the prior year-3.8% → -28.7%
- Earnings backed by cashOperating cash flow above net income-$60.07M vs -$74.88M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose22.63 → 27.40
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.31 → 0.00